-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure adds Legacy Health as US site for ProSense ChoICE low-risk breast cancer study

PUBT·10/06/2026 12:25:16
Listen to the news
IceCure adds Legacy Health as US site for ProSense ChoICE low-risk breast cancer study
  • IceCure added Legacy Health in Portland as a U.S. site for its ChoICE post-market study of ProSense cryoablation in low-risk breast cancer.
  • Results have not been presented; the study is ongoing and will generate additional real-world evidence on safety and effectiveness.
  • The trial aims to support ProSense as a minimally invasive alternative to surgery for eligible patients, potentially expanding adoption in breast cancer care.
  • ChoICE is planned to enroll about 400 patients across up to 30 U.S. clinical sites under a standardized protocol.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060825PR_NEWS_USPR_____LN64711) on October 06, 2026, and is solely responsible for the information contained therein.